ADC Therapeutics To Participate In The Guggenheim SMID Cap Biotech Conference
About ADC Therapeutics ADC Therapeutics (NYSE: ADCT ) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC ...
The American Journal of Managed Care20h
Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight
DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...
ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges
Adc Therapeutics SA stock has reached a 52-week low, trading at $1.61, as the company faces a challenging market environment. According to InvestingPro analysis, the stock's RSI indicates oversold ...
FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
pharmaphorum1h
Vertex bags FDA okay for its non-opioid pain drug
Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...